Wednesday, 28 October 2026Peptide medicines at the counter: price, coverage, supply, rules.
Peptide Town reports what changes when you try to get a peptide medicine such as Wegovy, Mounjaro or Zepbound: the price at the counter, who covers it, whether there is enough, the rules and the gray market. Every story is rated for the five kinds of reader it affects. How we rate
Walgreens will check insurance, file prior authorizations and call patients after the first GLP 1 fill. The $49 virtual visit does not include the drug, and Medicare Bridge help is limited by state.
RethinkHits pharmacies hardest: Pharmacists are asked to call every new GLP 1 patient and explain the Bridge claim reject step. Staffing is not described.
Five desks, one question each: what does it cost, who pays, is there enough, what is allowed, and who is selling copies.
What a month of treatment costs at the counter, list and cash, and who moved the number.
Insurers, public plans, employers and formularies: who pays, and on what terms.
Compounded copies, telehealth ads and sellers working at the edge of the rules.
Pick who you are. We show the stories that land hardest on you, and the one line that matters.
People who take the medicine, or want to, and pay some part of the bill.
All stories for patients
Rethink
NHS access for weight loss depends on your health board; most run no routine service and pilots are closed or small.
Rethink
Nothing changes yet: NHS access stays phased, and most eligible people still wait or pay privately.
Rethink
People prescribed Mounjaro for obesity keep paying the full price, about €179 to €300 a month; diabetes cover is unchanged.
Doctors, nurse practitioners and clinics who write the script and handle the paperwork.
All stories for prescribers
Rethink
New prescribing in general practice, with wraparound support required alongside the drug.
Rethink
Expect switch requests and exception paperwork for patients doing well on tirzepatide.
Adjust
Expect new eligibility rules and paperwork; the criteria are tied to weight plus related conditions.
Retail, mail-order and compounding pharmacies that stock, mix and hand over the box.
All stories for pharmacies
Rethink
Online pharmacies had to reprice quickly and manage a rush of early orders.
Rethink
State-licensed pharmacies had already passed their deadline; large outsourcing sites followed.
Rethink
Compounding these medicines is no longer allowed under the exemption that covered it.
Insurers, benefit managers, employers and public plans that decide what they cover.
All stories for payers
Rethink
Employers are told to review plan design and substitution rules now to capture any generic savings.
Rethink
A large saving for the state; other states watched closely.
Rethink
Public budgets avoid a large cost for now.
Makers, telehealth platforms and compounders that sell the product and set the price.
All stories for sellers
Rethink
Shows makers will cut ties with partners that keep selling copies.
Rethink
Answers Lilly’s vial channel with pens, not vials.
Rethink
Rivals lose access to some contract filling capacity they had used.
A weekly round-up is planned: five stories from the counter, each with the line that matters for you. Nothing is sent yet; join the waitlist and we will write when it starts.
